Doxazosin

May be taken with or without food.

History of orthostatic hypotension, benign prostatic hyperplasia (BPH) and concomitant upper urinary tract congestion, chronic urinary tract infection or bladder stones. As monotherapy in patients with overflow bladder, or anuria. Hypotension (when used for BPH).

Patient with angina pectoris, recent MI within the last 6 months, high-output heart failure, right-sided heart failure due to pulmonary embolism or pericardial effusion, left ventricular heart failure with low filling pressure, pulmonary oedema due to aortic or mitral stenosis; increased gastrointestinal retention, such as chronic constipation (for extended-release tab). Patient undergoing cataract surgery. Hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness, or weakness, if affected, do not drive or operate machinery. Monitoring Parameters Rule out prostate cancer before initiation of BPH therapy. Monitor blood pressure regularly and for at least 6 hours following the 1st dose and with each dose increase; CBC, LFTs and urinalysis. Assess for symptoms of hypotension regularly during treatment.

Significant: Orthostatic hypotension, syncope, CNS depression, intraoperative floppy iris syndrome (particularly in cataract surgery patients); hypersensitivity reactions, including pruritus, rash, angioedema, and respiratory effects; decreased WBC and neutrophil counts. Rarely, priapism. Cardiac disorders: Tachycardia, palpitations, chest pain. Ear and labyrinth disorders: Vertigo, tinnitus. Eye disorders: Visual disturbances. Gastrointestinal disorders: Nausea, abdominal pain, dyspepsia, dry mouth. General disorders and administration site conditions: Asthenia, peripheral oedema, fatigue, malaise, influenza-like symptoms. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, back pain, muscle cramps. Nervous system disorders: Headache, dizziness, drowsiness. Psychiatric disorders: Insomnia, anxiety. Renal and urinary disorders: UTI, urinary incontinence, cystitis, polyuria. Respiratory, thoracic and mediastinal disorders: Dyspnoea, respiratory tract infection, cough, bronchitis, rhinitis, epistaxis. Vascular disorders: Hypotension, flushing.

May result in symptomatic hypotension with phosphodiesterase-5 (PDE-5) inhibitors (e.g. sildenafil, tadalafil, vardenafil). Strong CYP3A4 inhibitors (e.g. clarithromycin, itraconazole, ritonavir, nelfinavir, telithromycin) may increase the serum concentration of doxazosin. May potentiate the hypotensive effects of other α₁-blockers and antihypertensive agents.

Drugs for Bladder & Prostate Disorders / Other Antihypertensives

C02CA04 - doxazosin ; Belongs to the class of alpha-adrenoreceptor antagonists, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.